Previous 10 | Next 10 |
Oncology Pharma (ONPH) announces that it has provided the initial financing for the initiation of formal drug development and preclinical planning based on the proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals.The licensed technology possesses proprietary technology ...
San Francisco, CA - ( NewMediaWire ) - March 31, 2021 - Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has provided the initial financing for the initiation of formal drug development and preclinical planning; based upon proprietary nanoemulsion technology licensed from Nano...
San Francisco, CA - ( NewMediaWire ) - March 16, 2021 - Oncology Pharma, Inc. (OTC: ONPH) revealed today the Company’s plans for growth and development of its intellectual property and business model. Key focal points include expansion of its cancer therapeutics through ...
Oncology Pharma (ONPH) announces that it is putting together a short list of contract research organizations ((CROs)) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization.Oncology Pharma expects that there ...
San Francisco, CA, March 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH): Today, the company announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications...
San Francisco, CA - ( NewMediaWire ) - March 04, 2021 - Oncology Pharma Inc. (OTC: ONPH) is pleased to announce initiation of formal drug development and preclinical planning for its lead drug product, based upon proprietary nanoemulsion technology licensed from NanoSmart Pharmaceutica...
Oncology Pharma (ONPH) has executed a world-wide Licensing Agreement with Sybleu for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agent.The chemotherapeutic agent is for the purpose of directly killing the tumo...
San Francisco, CA - ( NewMediaWire ) - February 26, 2021 - Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination ...
San Francisco, CA - ( NewMediaWire ) - February 22, 2021 - Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market. Nanosmart possesses...
San Francisco, CA - ( NewMediaWire ) - February 16, 2021 - Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. ...
News, Short Squeeze, Breakout and More Instantly...
Oncology Pharma Inc Company Name:
ONPH Stock Symbol:
OTCMKTS Market:
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the financing model towards the next step of the development process with its Nanoemulsion drug de...
SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to be reviewing the financing for taking the steps on moving forward with its development process of. the Nanoemulsuion Drug Delivery System. Many antican...
SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased that the initial feasibility stage is complete and results have met the threshold to move forward. The formulation under development consisted of the activ...